Fig. 2From: Targeting liver cancer stem cell through EpCAM therapy targeted with chemotherapy endorse enhanced progression in hepatocellular carcinomaa ABCG2 expression was drastically decreased in both EpCAM-targeted therapy compared than in cisplatin-treated cells. b ABCG2 a known chemoresistant marker was significantly decreased in XAV939-treated cells compared to the positive controlBack to article page